Mail

UK markets closed

FTSE 100
8,213.49
+41.34(+0.51%)
FTSE 250
20,164.54
+112.21(+0.56%)
AIM
771.53
+3.42(+0.45%)
GBP/EUR
1.1652
-0.0031(-0.26%)
GBP/USD
1.2546
+0.0013(+0.11%)
Bitcoin GBP
50,870.10
+1,834.98(+3.74%)

Best savings accounts that offer above inflation rates

Where to find a top-rated deal that works for you

Aclaris Therapeutics, Inc. (ACRS)

NasdaqGS - NasdaqGS Real-time price. Currency in USD

Add to watchlist

1.3600

+0.0500

(+3.82%)

At close: 04:00PM EDT

1.3800

+0.02

(+1.47%)

After hours:

07:56PM EDT

Currency in USD

Valuation measures⁴

Market cap (intra-day)	96.92M
Enterprise value	-21.76M
Trailing P/E	N/A
Forward P/E	N/A
PEG ratio (5-yr expected)	N/A
Price/sales (ttm)	3.04
Price/book (mrq)	0.62
Enterprise value/revenue	-0.70
Enterprise value/EBITDA	0.19

Trading information

Stock price history

Beta (5Y monthly)	0.23
52-week change ³	-84.40%
S&P500 52-week change ³	22.38%
52-week high ³	11.1200
52-week low ³	0.5900
50-day moving average ³	1.2232
200-day moving average ³	3.5770

Share statistics

Avg vol (3-month) ³	1.09M
Avg vol (10-day) ³	882.12k
Shares outstanding ⁵	71.26M
Implied shares outstanding ⁶	71.26M
Float ⁸	50.69M
% held by insiders ¹	2.48%
% held by institutions ¹	94.21%
Shares short (15 Apr 2024) ⁴	4.99M
Short ratio (15 Apr 2024) ⁴	6.68
Short % of float (15 Apr 2024) ⁴	8.11%
Short % of shares outstanding (15 Apr 2024) ⁴	7.04%
Shares short (prior month 15 Mar 2024) ⁴	5.12M

Dividends & splits

Forward annual dividend rate ⁴	N/A
Forward annual dividend yield ⁴	N/A
Trailing annual dividend rate ³	0.00
Trailing annual dividend yield ³	0.00%
5-year average dividend yield ⁴	N/A
Payout ratio ⁴	0.00%
Dividend date ³	N/A
Ex-dividend date ⁴	N/A
Last split factor ²	N/A
Last split date ³	N/A

Financial highlights

Fiscal year

Fiscal year ends	31 Dec 2023
Most-recent quarter (mrq)	31 Dec 2023

Profitability

Profit margin	-283.15%
Operating margin (ttm)	-134.99%

Management effectiveness

Return on assets (ttm)	-32.53%
Return on equity (ttm)	-49.88%

Income statement

Revenue (ttm)	31.25M
Revenue per share (ttm)	0.45
Quarterly revenue growth (yoy)	126.60%
Gross profit (ttm)	N/A
EBITDA	-117.56M
Net income avi to common (ttm)	-88.48M
Diluted EPS (ttm)	-1.2700
Quarterly earnings growth (yoy)	N/A

Balance sheet

Total cash (mrq)	119.11M
Total cash per share (mrq)	1.68
Total debt (mrq)	3.5M
Total debt/equity (mrq)	2.23%
Current ratio (mrq)	4.16
Book value per share (mrq)	2.22

Cash flow statement

Operating cash flow (ttm)	-78.33M
Levered free cash flow (ttm)	-39.92M